| Symbol | CRSP |
|---|---|
| Name | CRISPR THERAPEUTICS AG |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | BAARERSTRASSE 14, ZUG, 6300, Switzerland |
| Telephone | +41 41 - 561 32 77 |
| Fax | — |
| — | |
| Website | https://www.crisprtx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001674416 |
| Description | CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPRs most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes. Additional info from NASDAQ: |
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
Read more(30% Negative) CRISPR THERAPEUTICS AG (CRSP) Reports Q2 2026 Financial Results
Read moreCRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Read moreNew Form SCHEDULE 13G/A - CRISPR Therapeutics AG <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001104659-26-052492 <b>Size:</b> 13 KB
Read moreNew Form ARS - CRISPR Therapeutics AG <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001193125-26-165183 <b>Size:</b> 3 MB
Read moreNew Form DEFA14A - CRISPR Therapeutics AG <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001193125-26-165164 <b>Size:</b> 13 MB
Read moreNew Form DEF 14A - CRISPR Therapeutics AG <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001193125-26-165158 <b>Size:</b> 15 MB
Read moreNew Form PRE 14A - CRISPR Therapeutics AG <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001193125-26-140224 <b>Size:</b> 13 MB
Read moreKASINGER JAMES R. 🟡 adjusted position in 60.3K shares (3 derivative) of CRISPR Therapeutics AG (CRSP) at $46.78 ($1.9M) Transaction Date: Mar 20, 2026 | Filing ID: 122274
Read morePrasad Raju 🟡 adjusted position in 62.3K shares (3 derivative) of CRISPR Therapeutics AG (CRSP) at $46.78 ($2.0M) Transaction Date: Mar 20, 2026 | Filing ID: 122268
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07549698 | Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/R… | Phase1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | Not_Yet_Recruiting | 2026-04-01 | 2033-12-01 | ClinicalTrials.gov |
| NCT07549698 | Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/R… | Phase1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | Not_Yet_Recruiting | 2026-04-01 | 2033-12-01 | ClinicalTrials.gov |
| NCT06907875 | A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy | Phase1 | Facioscapulohumeral Muscular Dystrophy | Recruiting | 2025-05-08 | 2032-04-30 | ClinicalTrials.gov |
| NCT06907875 | A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy | Phase1 | Facioscapulohumeral Muscular Dystrophy | Recruiting | 2025-05-08 | 2032-04-30 | ClinicalTrials.gov |
| NCT06925542 | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory… | Phase1 | SLE (Systemic Lupus) | Recruiting | 2025-03-10 | 2031-12-31 | ClinicalTrials.gov |
| NCT06925542 | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory… | Phase1 | SLE (Systemic Lupus) | Recruiting | 2025-03-10 | 2031-12-31 | ClinicalTrials.gov |
| NCT06492304 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/R… | Phase1 | T Cell Lymphoma | Completed | 2024-08-13 | 2026-03-11 | ClinicalTrials.gov |
| NCT06492304 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/R… | Phase1 | T Cell Lymphoma | Completed | 2024-08-13 | 2026-03-11 | ClinicalTrials.gov |
| NCT07491172 | A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refracto… | Phase1 | Cardiovascular | Recruiting | 2024-06-21 | 2028-06-01 | ClinicalTrials.gov |
| NCT07491172 | A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refracto… | Phase1 | Cardiovascular | Recruiting | 2024-06-21 | 2028-06-01 | ClinicalTrials.gov |
| NCT06208878 | A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Ther… | — | Hematologic Malignancy | Enrolling_By_Invitation | 2023-11-22 | 2038-08-01 | ClinicalTrials.gov |
| NCT06208878 | A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Ther… | — | Hematologic Malignancy | Enrolling_By_Invitation | 2023-11-22 | 2038-08-01 | ClinicalTrials.gov |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed o… | Phase1 | Clear Cell Renal Cell Carcinoma | Completed | 2023-03-13 | 2025-09-18 | ClinicalTrials.gov |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed o… | Phase1 | Clear Cell Renal Cell Carcinoma | Completed | 2023-03-13 | 2025-09-18 | ClinicalTrials.gov |
| NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refr… | Phase1 | B-cell Lymphoma | Recruiting | 2023-03-10 | 2030-02-01 | ClinicalTrials.gov |
| NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refr… | Phase1 | B-cell Lymphoma | Recruiting | 2023-03-10 | 2030-02-01 | ClinicalTrials.gov |
| NCT05565248 | An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of V… | Phase1 | Diabetes Mellitus | Recruiting | 2023-01-20 | 2025-08-01 | ClinicalTrials.gov |
| NCT05565248 | An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of V… | Phase1 | Diabetes Mellitus | Recruiting | 2023-01-20 | 2025-08-01 | ClinicalTrials.gov |
| NCT05210530 | An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Com… | Phase1 | Diabetes Mellitus | Completed | 2022-01-24 | 2023-01-19 | ClinicalTrials.gov |
| NCT05210530 | An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Com… | Phase1 | Diabetes Mellitus | Completed | 2022-01-24 | 2023-01-19 | ClinicalTrials.gov |
| NCT04502446 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refr… | Phase1 | T Cell Lymphoma | Terminated | 2020-07-31 | 2024-08-30 | ClinicalTrials.gov |
| NCT04502446 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refr… | Phase1 | T Cell Lymphoma | Terminated | 2020-07-31 | 2024-08-30 | ClinicalTrials.gov |
| NCT04438083 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refr… | Phase1 | Renal Cell Carcinoma | Terminated | 2020-06-16 | 2024-10-08 | ClinicalTrials.gov |
| NCT04438083 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refr… | Phase1 | Renal Cell Carcinoma | Terminated | 2020-06-16 | 2024-10-08 | ClinicalTrials.gov |
| NCT04244656 | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refr… | Phase1 | Multiple Myeloma | Terminated | 2020-01-22 | 2024-01-04 | ClinicalTrials.gov |
| NCT04244656 | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refr… | Phase1 | Multiple Myeloma | Terminated | 2020-01-22 | 2024-01-04 | ClinicalTrials.gov |
| NCT04035434 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refr… | Phase1 | B-cell Malignancy | Terminated | 2019-07-22 | 2024-10-04 | ClinicalTrials.gov |
| NCT04035434 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refr… | Phase1 | B-cell Malignancy | Terminated | 2019-07-22 | 2024-10-04 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| VCTX210A unit | Other | Phase PHASE1 | Diabetes Mellitus | COMPLETED | NCT05210530 |
| VCTX211 | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT05565248 |
| CTX130 | Other | Phase PHASE1 | T Cell Lymphoma | TERMINATED | NCT04502446 |
| CTX130 | Other | Phase PHASE1 | Renal Cell Carcinoma | TERMINATED | NCT04438083 |
| CTX120 | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT04244656 |
| Non Interventional | Other | Preclinical | Hematologic Malignancy | ENROLLING_BY_INVITATION | NCT06208878 |
| CTX110 | Other | Phase PHASE1 | B-cell Malignancy | TERMINATED | NCT04035434 |
| CTX112 | Other | Phase PHASE1 | B-cell Lymphoma | RECRUITING | NCT05643742 |
| CTX131 | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | COMPLETED | NCT05795595 |
| CTX112 | Other | Phase PHASE1 | SLE (Systemic Lupus) | RECRUITING | NCT06925542 |
| CTX310 | Other | Phase PHASE1 | Cardiovascular | RECRUITING | NCT07491172 |
| CTX131 | Other | Phase PHASE1 | T Cell Lymphoma | COMPLETED | NCT06492304 |
| EPI-321 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| EPI-321 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| EPI-321 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| EPI-321 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| EPI-321 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| EPI-321 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| EPI-321 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| EPI-321 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| EPI-321 | BIOLOGICAL | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| CTX310 | DRUG | Phase PHASE1 | Cardiovascular | RECRUITING | NCT07491172 |
| Non Interventional | OTHER | Preclinical | Hematologic Malignancy | ENROLLING_BY_INVITATION | NCT06208878 |
| CTX131 | BIOLOGICAL | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | COMPLETED | NCT05795595 |
| CTX112 | BIOLOGICAL | Phase PHASE1 | B-cell Lymphoma | RECRUITING | NCT05643742 |
| CTX130 | BIOLOGICAL | Phase PHASE1 | T Cell Lymphoma | TERMINATED | NCT04502446 |
| CTX120 | BIOLOGICAL | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT04244656 |
| CTX110 | BIOLOGICAL | Phase PHASE1 | B-cell Malignancy | TERMINATED | NCT04035434 |